CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
MIV-711drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03037489
NCT03037489Phase 2Completed
CompareCT.gov

An Open-Label, One-Arm Phase II Extension Study to Evaluate Safety and Tolerability of MIV-711 in Patients With Knee Joint Osteoarthritis

Medivir·interventional·Posted Jan 31, 2017·Updated Mar 18, 2019

In Brief

A Phase 2 clinical trial evaluating MIV-711 for Osteoarthritis, Knee. Completed, enrolled 50 participants across 4 sites in 4 countries.

Detailed Summary

This is a multicentre, open-label, one-arm Phase II extension study to evaluate the safety and tolerability of MIV-711 in patients with knee joint osteoarthritis (OA).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Knee
CountriesBulgaria, Georgia, Germany, Moldova
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 31, 2017
Enrollment StartSep 1, 2016
Primary CompletionNov 28, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.4 years ago

Interventions

MIV-711drug

MIV-711 administered orally once daily